These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30145711)

  • 1. Novel Fubinaca/Rimonabant hybrids as endocannabinoid system modulators.
    Stefanucci A; Macedonio G; Dvorácskó S; Tömböly C; Mollica A
    Amino Acids; 2018 Nov; 50(11):1595-1605. PubMed ID: 30145711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Description of a bivalent cannabinoid ligand with hypophagic properties.
    Fernández-Fernández C; Decara J; Bermúdez-Silva FJ; Sánchez E; Morales P; Gómez-Cañas M; Gómez-Ruíz M; Callado LF; Goya P; Rodríguez de Fonseca F; Martín MI; Fernández-Ruíz J; Meana JJ; Jagerovic N
    Arch Pharm (Weinheim); 2013 Mar; 346(3):171-9. PubMed ID: 23371794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
    Alvarado M; Decara J; Luque MJ; Hernandez-Folgado L; Gómez-Cañas M; Gómez-Ruiz M; Fernández-Ruiz J; Elguero J; Jagerovic N; Serrano A; Goya P; de Fonseca FR
    Bioorg Med Chem; 2013 Apr; 21(7):1708-16. PubMed ID: 23434135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.
    Iyer MR; Cinar R; Liu J; Godlewski G; Szanda G; Puhl H; Ikeda SR; Deschamps J; Lee YS; Steinbach PJ; Kunos G
    Mol Pharmacol; 2015 Aug; 88(2):238-44. PubMed ID: 26013543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
    Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
    Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
    Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
    Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant.
    Paquette JJ; Wang HY; Bakshi K; Olmstead MC
    Behav Pharmacol; 2007 Dec; 18(8):767-76. PubMed ID: 17989514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors.
    Mussinu JM; Ruiu S; Mulè AC; Pau A; Carai MA; Loriga G; Murineddu G; Pinna GA
    Bioorg Med Chem; 2003 Jan; 11(2):251-63. PubMed ID: 12470719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
    Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
    J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands.
    Song KS; Kim MJ; Seo HJ; Lee SH; Jung ME; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2009 Apr; 17(8):3080-92. PubMed ID: 19328001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
    Fulp A; Bortoff K; Seltzman H; Zhang Y; Mathews J; Snyder R; Fennell T; Maitra R
    J Med Chem; 2012 Mar; 55(6):2820-34. PubMed ID: 22372835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cannabinoid receptors 1 modulation on osteoporosis in a rat model of different ages.
    Samir SM; Malek HA
    J Physiol Pharmacol; 2014 Oct; 65(5):687-94. PubMed ID: 25371528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors.
    Murineddu G; Ruiu S; Mussinu JM; Loriga G; Grella GE; Carai MA; Lazzari P; Pani L; Pinna GA
    Bioorg Med Chem; 2005 May; 13(9):3309-20. PubMed ID: 15809166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking the cannabinoid receptors: drug candidates and therapeutic promises.
    Muccioli GG
    Chem Biodivers; 2007 Aug; 4(8):1805-27. PubMed ID: 17712820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.